Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Prior Therapies for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations

NCT04963153 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04963153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04963153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Trial of Erdafitinib Combined With Enfortumab Vedotin Following Prior Therapies for Metastatic Urothelial Carcinoma With FGFR2/3 Genetic Alterations
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 7, 2022
Completion date
December 1, 2026
Enrollment
24 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced bladder urothelial carcinoma, locally advanced renal pelvis urothelial carcinoma, locally advanced ureter urothelial carcinoma, locally advanced urethral urothelial carcinoma, locally advanced urothelial carcinoma, metastatic bladder urothelial carcinoma, metastatic renal pelvis urothelial carcinoma, metastatic ureter urothelial carcinoma, metastatic urethral urothelial carcinoma, metastatic urothelial carcinoma, recurrent bladder urothelial carcinoma, recurrent renal pelvis urothelial carcinoma, recurrent ureter urothelial carcinoma, recurrent urethral urothelial carcinoma, recurrent urothelial carcinoma, stage iiib bladder cancer ajcc v8, stage iv bladder cancer ajcc v8, stage iv renal pelvis cancer ajcc v8, stage iv ureter cancer ajcc v8, stage iv urethral cancer ajcc v8